Edition:
United States

Edwards Lifesciences Corp (EW)

EW on New York Consolidated

83.35USD
2 Dec 2016
Change (% chg)

$1.88 (+2.31%)
Prev Close
$81.47
Open
$81.44
Day's High
$84.66
Day's Low
$81.25
Volume
2,324,500
Avg. Vol
1,848,110
52-wk High
$121.75
52-wk Low
$72.20

Latest Key Developments (Source: Significant Developments)

FDA approves expanded indication for Sapien XT and Sapien 3 transcatheter heart valves
Thursday, 18 Aug 2016 02:37pm EDT 

U.S. FDA : U.S. Food and Drug Administration today approved an expanded indication for the Sapien XT and Sapien 3 transcatheter heart valves .Requiring Edwards to conduct post-approval study to follow patients treated with either device in first,second clinical studies for 10 years.  Full Article

EDWARDS INTUITY Elite Rapid Deployment Valve receives FDA approval
Monday, 15 Aug 2016 08:30am EDT 

Edwards Lifesciences Corp :Edwards INTUITY Elite Rapid Deployment Valve receives FDA approval.  Full Article

Edwards Lifesciences Q2 Adjusted EPS $0.76
Tuesday, 26 Jul 2016 04:15pm EDT 

Edwards Lifesciences Corp : Sees Q3 Sales Between $720 Mln - $760 Mln; Sees Q3 Adjusted Earnings Per Share Between $0.62 - $0.68 . Q3 Earnings Per Share View $0.64, Revenue View $708.1 Million; Fy2016 Earnings Per Share View $2.76, Revenue View $2.89 Billion -- Thomson Reuters I/B/E/S . Q2 Transcatheter Heart Valve Therapy Sales Of $418.6 Million, Up 48.7 Percent From Previous Year . Edwards Lifesciences Corp Q2 Earnings Per Share $0.58, Q2 Adjusted Earnings Per Share $0.76; Q2 Sales $759.3 Million, Up 23.1 Percent From Previous Year . Sees 2016 Total Sales At High End Of $2.7 Billion-$3.0 Billion; Sees 2016 Adjusted Earnings Per Share $2.78 - $2.88 .Q2 Earnings Per Share View $0.70, Revenue View $724.3 Million -- Thomson Reuters I/B/E/S.  Full Article

Edwards Lifesciences says jury returns verdict in favor of CardiAQ in case with Neovasc
Thursday, 19 May 2016 07:47pm EDT 

Edwards Lifesciences Corp : Federal jury in Boston returned a verdict in favor of CardiAQ in lawsuit filed against a former service provider, Neovasc . Jury awarded damages of $70 million for trade secret misappropriation ."Jury found that Neovasc breached non-disclosure agreement between parties, misappropriated CardiAQ's trade secrets".  Full Article

Edwards Lifesciences Corp gives Q4 2015 guidance in line with analysts' estimates; reaffirms FY 2015 revenue guidance; raises FY 2015 EPS guidance
Monday, 26 Oct 2015 04:15pm EDT 

Edwards Lifesciences Corp:Continues to expect FY 2015 total sales to be between $2.3 billion to $2.5 billion.Increases its guidance for FY 2015 diluted earnings per share, excluding special items, to a range of $4.43 to $4.53, from its previous range of $4.30 to $4.40.Says for Q4 2015, at current foreign exchange rates, the company projects total sales to be between $620 million and $660 million, and diluted earnings per share, excluding special items, to be between $1.11 and $1.21.Q4 2015 revenue of $631 million and EPS of $1.14 - Thomson Reuters I/B/E/S.FY 2015 revenue of $2.44 billion and EPS of $4.37 - Thomson Reuters I/B/E/S.  Full Article

Edwards Lifesciences Corp reaffirms FY 2015 sales outlook; raises FY 2015 EPS out look; gives Q3 2015 guidance
Tuesday, 28 Jul 2015 04:01pm EDT 

Edwards Lifesciences Corp:Expects FY 2015 total sales to be within original guidance of $2.3 billion to $2.5 billion.Increases FY 2015 diluted earnings per share, excluding special items, to a range of $4.30 to $4.40, from its previous range of $4.10 to $4.30.Expects Q2 2015 total sales to be between $580 million and $620 million.Expects Q2 2015 diluted earnings per share, excluding special items, to be between $0.92 and $1.00.FY 2015 revenue of $2.4 bln and EPS of $4.27 -Thomson Reuters I/B/E/S.Q2 2015 revenue of $587 mln and EPS of $0.98 -Thomson Reuters I/B/E/S.  Full Article

Edwards Lifesciences Corp enters into agreement to acquire CardiAQ Valve Technologies
Friday, 10 Jul 2015 05:00pm EDT 

Edwards Lifesciences Corp:Announced that it has agreed to acquire CardiAQ Valve Technologies, Inc.Purchase price is up to $400 million, including $350 million in cash at closing, and the remainder payable upon achievement of a European regulatory milestone.Expects that this acquisition will be slightly dilutive to 2015 earnings per share.  Full Article

Edwards Lifesciences Corp receives FDA approval for SAPIEN 3 transcatheter heart valve
Wednesday, 17 Jun 2015 07:07pm EDT 

Edwards Lifesciences Corp:Says U.S. Food and Drug Administration (FDA) approval of its most advanced transcatheter aortic heart valve - Edwards SAPIEN 3 valve with Commander Delivery System - for treatment of high-risk patients suffering from severe, symptomatic aortic stenosis.  Full Article

Edwards Lifesciences Corp reaffirms FY 2015 sales outlook , raises low end of prior FY 2015 EPS outlook; gives Q2 2015 outlook
Thursday, 23 Apr 2015 04:01pm EDT 

Edwards Lifesciences Corp:Expects FY 2015 total sales to be within original guidance of $2.3 billion to $2.5 billion.Narrowed FY 2015 diluted earnings per share, excluding special items, to a range of $4.10 to $4.30 from its previous range of $4.00 to $4.30.Expects Q2 2015 total sales to be between $580 million and $620 million.Expects Q2 2015 diluted earnings per share, excluding special items, to be between $1.00 and $1.10.FY 2015 revenue of $2.3 bln and EPS of $4.21 -Thomson Reuters I/B/E/S.Q2 2015 revenue of $604 mln and EPS of $1.05 -Thomson Reuters I/B/E/S.  Full Article

Edwards Lifesciences Corp sees FY 2015 sales outlook at lower end of prior range, raises EPS outlook; gives Q1 2015 outlook, EPS below analysts' estimates
Tuesday, 3 Feb 2015 04:01pm EST 

Edwards Lifesciences Corp:Now expects FY 2015 reported sales to be at the lower end of its previously provided $2.3 to $2.5 billion range.Based on current foreign exchange rates, the company expects an about $160 million negative impact to FY 2015 reported sales compared to the prior year.Also is raising FY 2015 diluted EPS guidance to $4.00 to $4.30, excluding special items.FY 2015 revenue of $2.42 bln and EPS of $3.99 -Thomson Reuters I/B/E/S.Expects Q1 2015 total sales to be between $570 and $610 million.Q1 2015 diluted earnings per share, excluding special items, to be between $1.02 and $1.10.Q1 2015 revenue of $580 mln and EPS of $0.92 -Thomson Reuters I/B/E/S.  Full Article

Edwards Lifesciences to buy Israel's Valtech for up to $690 million

JERUSALEM Edwards Lifesciences Corp on Monday said it has agreed to buy Israel's Valtech Cardio for $340 million in stock and cash, with the potential for an additional $350 million in pre-specified milestone-driven payments over the next 10 years.